Beta Bionics (NASDAQ:BBNX) Now Covered by Analysts at Stifel Nicolaus

Stock analysts at Stifel Nicolaus initiated coverage on shares of Beta Bionics (NASDAQ:BBNX - Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat reports. The brokerage set a "buy" rating and a $25.00 price target on the stock. Stifel Nicolaus' price target suggests a potential upside of 25.57% from the stock's current price.

Several other brokerages also recently commented on BBNX. Baird R W upgraded shares of Beta Bionics to a "hold" rating in a research report on Thursday, February 20th. Piper Sandler initiated coverage on Beta Bionics in a research report on Monday. They issued an "overweight" rating and a $26.00 price objective on the stock. Leerink Partners started coverage on Beta Bionics in a research report on Monday. They set an "outperform" rating and a $28.00 target price for the company. Robert W. Baird initiated coverage on Beta Bionics in a report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target on the stock. Finally, LADENBURG THALM/SH SH initiated coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a "neutral" rating and a $20.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $24.83.

Remove Ads

Beta Bionics Price Performance

Beta Bionics stock traded down $0.08 during midday trading on Monday, hitting $19.91. The stock had a trading volume of 389,619 shares, compared to its average volume of 332,212. Beta Bionics has a 52-week low of $18.67 and a 52-week high of $24.50.

Insider Buying and Selling at Beta Bionics

In related news, major shareholder Hadley Harbor Aggre Wellington acquired 1,000,000 shares of Beta Bionics stock in a transaction on Friday, January 31st. The shares were bought at an average cost of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the purchase, the insider now directly owns 3,901,599 shares of the company's stock, valued at $66,327,183. The trade was a 34.46 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Mike Mensinger acquired 33,350 shares of the firm's stock in a transaction on Friday, January 31st. The shares were bought at an average price of $17.00 per share, for a total transaction of $566,950.00. Following the completion of the transaction, the insider now owns 59,019 shares of the company's stock, valued at approximately $1,003,323. This trade represents a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.